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a skin deterioration (ﬂare). METHODS: Multi-centre,
cross-sectional, prospective QoL study. Information
including demographic and disease characteristics was
collected with semi-structured patient questionnaire 
and by chart abstraction. Disease-speciﬁc instruments:
PIQoL-AD (Parents Index Quality of Life—Atopic Der-
matitis; score: 0–28 points) for parents of children up to
8 years, QoLIAD (Quality of Life Index Atopic Dermati-
tis; score: 0–25 points) for patients over 16 years. CDLQI
(Children Dermatology Life Quality Index; score: 0–30
points) was used for patients aged 9–16 years. Higher
scores indicate greater impairment of QoL. EQ-5D was
used to assess preferences (utilities) of patients over 16
years. RESULTS: A total of 193 patients enrolled at 
16 centers (10 ofﬁce-based dermatologists, 4 ofﬁce-based
paediatricians, 1 outpatient unit of a dermatology hospi-
tal, 1 patient organization) sent back the questionnaires.
Mean age (range): 23 years (1–71 years), 63% female.
27% of the patients had a mild, 38% a moderate and
35% a severe course of disease. Median duration of
current ﬂare: 12 days. Mean utility value during a ﬂare
was 0.69 (SD 0.26). After ﬂare mean utility value rose up
to 0.82 (SD 0.17). Atopic dermatitis-speciﬁc instruments
(PIQoL-AD/QoLIAD) showed reductions in QoL during
a ﬂare in comparison to the period after ﬂare: 10.2 (SD
7.3) vs. 6.4 (SD 6.1)/11.4 (SD 7.2) vs. 7.5 (SD 6.6).
Patients aged 9–16 years (CDLQI) reported comparable
impairment of QoL during (9.8, SD 3.8) and after a ﬂare
(9.6, SD 3.9). CONCLUSIONS: Patients’ and parents’
QoL is reduced considerably during a ﬂare of atopic der-
matitis. Health status (utility value) of patients during a
ﬂare is comparable to health status of patients with other
chronic diseases like e.g. diabetes type II.
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OBJECTIVES: To estimate the incremental costs and
incremental health effects of replacing methotrexate
(MTX) by alefacept (Amevive) in patients with moderate
to severe psoriasis (PASI-score 10+). METHODS: A total
of 36 patients with moderate to severe psoriasis were
interviewed about quality of life and treatment costs.
Disease severity was measured by PASI-score (Psoriasis
Area and Severity Index) while quality of life was mea-
sured by a multiattribute utility instrument (15D) and a
disease speciﬁc instrument (DLQI-N). Cost of psoriasis
therapy during the past three months was estimated on
the basis of patients’ utilization reports and unit costs. A
Markov model with 4 health states based on PASI-score
(0, 1–9, 10–19, 20+), 12 weeks cycles and 2 years time
horizon was developed. Transition probabilities were
derived from published clinical trials (MTX and ale-
facept) and websites (alefacept), but no head-to-head
trials were available. The beneﬁt from psoriasis therapy
was expressed in terms of QALYs, and sensitivity analy-
ses were used to explore the robustness of the results.
RESULTS: Quality of life was estimated at 0.94, 0.91,
0.88, and 0.77 in the four PASI-groups. Average 3 months
psoriasis treatment costs were $384, $509, and $960 for
patients with PASI-score 1–9, 10–19, 20+ respectively. In
the base case, alefacept has higher costs and lower health
beneﬁt, and this result was fairly robust to a wide range
of changes in the model parameters. Only when all para-
meters values were assumed as favourable as conceivable
for alefacept and as unfavourable as conceivable for
MTX, the cost per QALY came down to $76,400. CON-
CLUSION: Alefacept seems to represent greater costs and
smaller health beneﬁts than MTX in patients with mod-
erate to severe psoriasis. There is an urgent need to
conﬁrm these results in head-to-head trials of MTX and
alefacept.
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OBJECTIVE: To describe quality of life (QoL) and
patients’ preferences in psoriasis patients with current
skin deterioration and 6 weeks later after subsequent
therapy. METHODS: Prospective, multi-center, cross-sec-
tional, quality of life study combined with a cost-of-illness
study. Patients (over 17 years; with moderate and severe
course of disease) were enrolled consecutively by 12
ofﬁce-based dermatologists and by 5 outpatient depart-
ments in dermatology hospitals. Instruments: DLQI (Der-
matology Life Quality Index; sum score: 0–30 points; 0
= no reductions in QoL), EQ-5D, semi-structured patient
questionnaire. RESULTS: A total of 227 patients were
enrolled. 197 sent back the quality of life questionnaire
part A (within current skin deterioration) and 151
patients part B (6 weeks later). Mean age were 47 years,
55% were male. Mean DLQI score during the current
skin deterioration accounted 9.3 (SD 6.8) and varied from
0 to 27 points; 6 weeks later DLQI score decreased to 6.8
(SD 5.2). The mean utility value was 0.79 (SD 0.18) at
enrollment due to current skin deterioration and showed
the same ﬁgure 6 weeks later (0.80, SD 0.17). DLQI score
indicated greater reductions of QoL due to a current skin
deterioration in patients with severe course of psoriasis
(10.4, SD 7.1) than in patients with moderate form of
psoriasis (8.4, SD 6.4). Mean DLQI score decreased from
9.1 (SD 6.8) to 7.0 (SD 5.7) in patients with topical treat-
ment and/or phototherapy within 6 weeks. In patients
treated with systemic medication additionally, mean
DLQI score fell from 8.3 (SD 5.6) to 5.7 (SD 4.0). CON-
CLUSIONS: The considerable reduction in QoL due to a
